{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:53:30Z","timestamp":1764996810687},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2003,8]]},"DOI":"10.1007\/s11938-003-0025-6","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T18:25:44Z","timestamp":1180895144000},"page":"329-337","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of irritable bowel syndrome"],"prefix":"10.1007","volume":"6","author":[{"given":"Robin C.","family":"Spiller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"suppl 2","key":"25_CR1","first-page":"II1","volume":"47","author":"J Jones","year":"2000","unstructured":"Jones J, Boorman J, Cann P, et al.: British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 2000, 47(suppl 2):II1-II19. Comprehensive review of epidemiology and treatment, with practical guide to management and when to refer for further investigation.","journal-title":"Gut"},{"key":"25_CR2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.46.1.78","volume":"46","author":"WG Thompson","year":"2000","unstructured":"Thompson WG, Heaton KW, Smyth GT, Smyth C: Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000, 46:78\u201382. Detailed unique account of how irritable bowel syndrome presents and is diagnosed in primary care.","journal-title":"Gut"},{"key":"25_CR3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/fampra\/13.1.12","volume":"13","author":"AM Dulmen Van","year":"1996","unstructured":"Van Dulmen AM, Fennis JM, Mokkink HA, Bleijenberg G: The relationship between complaint-related cognitions in referred patients with irritable bowel syndrome and subsequent health care seeking behaviour in primary care. Fam Pract 1996, 13:12\u201317.","journal-title":"Fam Pract"},{"issue":"suppl 2","key":"25_CR4","first-page":"II43","volume":"45","author":"WG Thompson","year":"1999","unstructured":"Thompson WG, Longstreth GF, Drossman DA, et al.: Functional bowel disorders and functional abdominal pain. Gut 1999, 45(suppl 2):II43\u201347.","journal-title":"Gut"},{"key":"25_CR5","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1111\/j.1572-0241.1999.01437.x","volume":"94","author":"SJ Vanner","year":"1999","unstructured":"Vanner SJ, Depew WT, Paterson WG, et al.: Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999, 94:2912\u20132917.","journal-title":"Am J Gastroenterol"},{"key":"25_CR6","first-page":"15","volume":"4","author":"KK Kapoor","year":"1985","unstructured":"Kapoor KK, Nigam P, Rastogi CK, et al.: Clinical profile of irritable bowel syndrome. Indian J Gastroenterol 1985, 4:15\u201316.","journal-title":"Indian J Gastroenterol"},{"key":"25_CR7","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/003655299750025093","volume":"34","author":"G Ragnarsson","year":"1999","unstructured":"Ragnarsson G, Bodemar G: Division of the irritable bowel syndrome into subgroups on the basis of daily recorded symptoms in two outpatients samples. Scand J Gastroenterol 1999, 34:993\u20131000.","journal-title":"Scand J Gastroenterol"},{"key":"25_CR8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/gut.24.5.405","volume":"24","author":"PA Cann","year":"1983","unstructured":"Cann PA, Read NW, Brown C: Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 1983, 24:405\u2013411.","journal-title":"Gut"},{"key":"25_CR9","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/0016-5085(95)90134-5","volume":"108","author":"HH Wenzl","year":"1995","unstructured":"Wenzl HH, Fine KD, Schiller LR, Fordtran JS: Determinants of decreased fecal consistency in patients with diarrhea. Gastroenterology 1995, 108:1729\u20131738.","journal-title":"Gastroenterology"},{"key":"25_CR10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/gut.43.2.256","volume":"43","author":"EJ Bennett","year":"1998","unstructured":"Bennett EJ, Tennant CC, Piesse C, et al.: Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998, 43:256\u2013261.","journal-title":"Gut"},{"key":"25_CR11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00042737-199704000-00006","volume":"9","author":"M Delvaux","year":"1997","unstructured":"Delvaux M, Denis P, Allemand H: Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive diseases or controls. Results of a multicentre inquiry. French Club of Digestive Motility. Eur J Gastroenterol Hepatol 1997, 9:345\u2013352.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"25_CR12","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/BF01263095","volume":"23","author":"FJ Simoons","year":"1978","unstructured":"Simoons FJ: The geographic hypothesis and lactose malabsorption a weighing of the evidence. Dig Dis Sci 1978, 23:963\u2013979.","journal-title":"Dig Dis Sci"},{"key":"25_CR13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00042737-200103000-00001","volume":"13","author":"TJ Parker","year":"2001","unstructured":"Parker TJ, Woolner JT, Prevost AT, et al.: Irritable bowel syndrome: is the search for lactose intolerance justified? Eur J Gastroenterol Hepatol 2001, 13:219\u2013225.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"25_CR14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(94)91055-3","volume":"344","author":"CY Francis","year":"1994","unstructured":"Francis CY, Whorwell PJ: Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994, 344:39\u201340.","journal-title":"Lancet"},{"key":"25_CR15","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(98)02146-1","volume":"352","author":"TS King","year":"1998","unstructured":"King TS, Elia M, Hunter JO: Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998, 352:1187\u20131189.","journal-title":"Lancet"},{"key":"25_CR16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-277X.1995.tb00308.x","volume":"8","author":"TJ Parker","year":"1995","unstructured":"Parker TJ, Naylor SJ, Riordan AM, Hunter JO: Management of patients with food intolerance in irritable bowel syndrome: the development and use of an exclusion diet. J Hum Nutr Diet 1995, 8:159\u2013166.","journal-title":"J Hum Nutr Diet"},{"key":"25_CR17","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/gut.30.8.1099","volume":"30","author":"R Nanda","year":"1989","unstructured":"Nanda R, James R, Smith H, et al.: Food intolerance and the irritable bowel syndrome. Gut 1989, 30:1099\u20131104.","journal-title":"Gut"},{"key":"25_CR18","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1572-0241.2000.02015.x","volume":"95","author":"S Nobaek","year":"2000","unstructured":"Nobaek S, Johansson ML, Molin G, et al.: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000, 95:1231\u20131238.","journal-title":"Am J Gastroenterol"},{"key":"25_CR19","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/00042737-200110000-00004","volume":"13","author":"K Niedzielin","year":"2001","unstructured":"Niedzielin K, Kordecki H, Birkenfeld B: A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001, 13:1143\u20131147.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"25_CR20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1192\/bjp.163.3.315","volume":"163","author":"E Guthrie","year":"1993","unstructured":"Guthrie E, Creed F, Dawson D, Tomenson B: A randomised controlled trial of psychotherapy in patients with refractory irritable bowel syndrome. Br J Psychiatry 1993, 163:315\u2013321.","journal-title":"Br J Psychiatry"},{"key":"25_CR21","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/S0140-6736(84)92793-4","volume":"2","author":"PJ Whorwell","year":"1984","unstructured":"Whorwell PJ, Prior A, Faragher EB: Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet 1984, 2:1232\u20131234.","journal-title":"Lancet"},{"key":"25_CR22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/gut.28.4.423","volume":"28","author":"PJ Whorwell","year":"1987","unstructured":"Whorwell PJ, Prior A, Colgan SM: Hypnotherapy in severe irritable bowel syndrome: further experience. Gut 1987, 28:423\u2013425.","journal-title":"Gut"},{"key":"25_CR23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/00365528709091004","volume":"22","author":"N Hovdenak","year":"1987","unstructured":"Hovdenak N: Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol 1987, 22(suppl):81\u201384.","journal-title":"Scand J Gastroenterol"},{"key":"25_CR24","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1007\/BF02209014","volume":"40","author":"M Dapoigny","year":"1995","unstructured":"Dapoigny M, Abitbol JL, Fraitag B: Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter doseresponse study. Dig Dis Sci 1995, 40:2244\u20132249.","journal-title":"Dig Dis Sci"},{"key":"25_CR25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2036.1994.tb00323.x","volume":"8","author":"J Snook","year":"1997","unstructured":"Snook J, Shepherd HA: Brain supplementation in the treatment of irritable bowel syndrome. Alimentary Pharmacol Ther 1997, 8:511\u2013514.","journal-title":"Alimentary Pharmacol Ther"},{"key":"25_CR26","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1136\/gut.28.11.1510","volume":"28","author":"A Prior","year":"1987","unstructured":"Prior A, Whorwell PJ: Double blind study of ispaghula in irritable bowel syndrome. Gut 1987, 28:1510\u20131513.","journal-title":"Gut"},{"key":"25_CR27","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/j.1572-0241.2001.04128.x","volume":"96","author":"T Lembo","year":"2001","unstructured":"Lembo T, Wright RA, Bagby B, et al.: Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001, 96:2662\u20132670.","journal-title":"Am J Gastroenterol"},{"key":"25_CR28","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","volume":"161","author":"M Camilleri","year":"2001","unstructured":"Camilleri M, Chey WY, Mayer EA, et al.: A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001, 161:1733\u20131740. Large, well-conducted study that should serve as a model for future irritable bowel syndrome (IBS) trials showing benefit, especially in diarrhea-predominant IBS.","journal-title":"Arch Intern Med"},{"key":"25_CR29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0016-5085(00)70251-4","volume":"118","author":"CM Prather","year":"2000","unstructured":"Prather CM, Camilleri M, Zinsmeister AR, et al.: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000, 118:463\u2013468.","journal-title":"Gastroenterology"},{"key":"25_CR30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2036.2001.00925.x","volume":"15","author":"M Camilleri","year":"2001","unstructured":"Camilleri M: Review article: tegaserod. Aliment Pharmacol Ther 2001, 15:277\u2013289. Detailed account of pharmacology and clinical effects of this new 5-HT4 agonist.","journal-title":"Aliment Pharmacol Ther"},{"key":"25_CR31","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","volume":"15","author":"SA Muller-Lissner","year":"2001","unstructured":"Muller-Lissner SA, Fumagalli I, Bardhan KD, et al.: Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001, 15:1655\u20131666.","journal-title":"Aliment Pharmacol Ther"},{"key":"25_CR32","first-page":"H2534","volume":"273","author":"S Mohammad","year":"1997","unstructured":"Mohammad S, Zhou Z, Gong Q, January CT: Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997, 273:H2534-H2538.","journal-title":"Am J Physiol"},{"key":"25_CR33","doi-asserted-by":"crossref","first-page":"A10","DOI":"10.1136\/gut.51.suppl_5.v10","volume":"51","author":"NL Meyer","year":"2002","unstructured":"Meyer NL, Tack J, Middleton S, et al.: Efficacy and safety of renzapride in patients with constipation-predominant irritable bowel syndrome. Gut 2002, 51:A10.","journal-title":"Gut"},{"key":"25_CR34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2036.1994.tb00308.x","volume":"8","author":"RE Clouse","year":"1994","unstructured":"Clouse RE, Lustman PJ, Geisman RA, Alpers DH: Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994, 8:409\u2013416.","journal-title":"Aliment Pharmacol Ther"},{"key":"25_CR35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-133-2-200007180-00013","volume":"133","author":"J Jailwala","year":"2000","unstructured":"Jailwala J, Imperiale TF, Kroenke K: Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000, 133:136\u2013147. Useful brief summary of previous trials indicating the likely size of benefit from each drug class.","journal-title":"Ann Intern Med"},{"key":"25_CR36","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/00365529609006404","volume":"31","author":"L Tanum","year":"1996","unstructured":"Tanum L, Malt UF: A new pharmacologic treatment of functional gastrointestinal disorder: A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol 1996, 31:318\u2013325.","journal-title":"Scand J Gastroenterol"},{"key":"25_CR37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/gast.2003.50055","volume":"124","author":"F Creed","year":"2003","unstructured":"Creed F, Fernandes L, Guthrie E, et al.: The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003, 124:303\u2013317.","journal-title":"Gastroenterology"},{"key":"25_CR38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-2036.2001.00937.x","volume":"15","author":"T Poynard","year":"2001","unstructured":"Poynard T, Regimbeau C, Benhamou Y: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001, 15:355\u2013361.","journal-title":"Aliment Pharmacol Ther"},{"key":"25_CR39","first-page":"A981","volume":"116","author":"M D\u2019Amato","year":"1999","unstructured":"D\u2019Amato M, Whorwell P, Thompson D, et al.: The CCKA receptor antagonist dexloxiglumide in the treatment of IBS [abstract]. Gastroenterology 1999, 116:A981.","journal-title":"Gastroenterology"},{"key":"25_CR40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(86)90673-2","volume":"1","author":"GF Stefanini","year":"1986","unstructured":"Stefanini GF, Bazzocchi G, Prati E: Efficacy of oral disodium cromoglycate in patients with irritable bowel syndrome and positive skin prick tests to foods. Lancet 1986, 1:207\u2013208.","journal-title":"Lancet"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-003-0025-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-003-0025-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-003-0025-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:56:58Z","timestamp":1559437018000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-003-0025-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["25"],"URL":"https:\/\/doi.org\/10.1007\/s11938-003-0025-6","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8]]}}}